Clinical Trial Update: A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating HRS-6208 in combination with HRS-8080, or with Fulvestrant or Letrozole, with or without HRS-6209, in adults with advanced unresect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• HRS-6208 (HRS-6208)
• HRS-6209 (HRS-6209)
• HRS-8080
• Letrozole (letrozole)

Snippet

Sponsor: Shandong Suncadia Medicine Co., Ltd. | Conditions: Advanced Unresectable or Metastatic Breast Cancer of Adults | Phase 1, Phase 2 | Status: RECRUITING